NIH -- Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia [http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml] and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health’s National Institute of Mental Health (NIMH). The study was published online September 15, 2008, in the American Journal of Psychiatry.
